Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

June 13, 2023

Primary Completion Date

October 13, 2024

Study Completion Date

October 13, 2024

Conditions
Overweight or Obesity
Interventions
DRUG

HRS9531 injection

HRS9531 injection: dose level 1 for 32 weeks、level 2 for 20 weeks

DRUG

HRS9531 injection

HRS9531 injection: dose level 2

DRUG

HRS9531 injection

HRS9531 injection: dose level 3

DRUG

HRS9531 injection

HRS9531 injection: dose level 4

DRUG

HRS9531 injection Placebo

Placebo arm matching active arm HRS9531 injection dose level 1 for 32 weeks、HRS9531 injection level 2 for 20 weeks

DRUG

HRS9531 injection Placebo

Placebo arm matching active arm HRS9531 injection dose level 2 for 32 weeks、HRS9531 injection level 2 for 20 weeks

DRUG

HRS9531 injection Placebo

Placebo arm matching active arm HRS9531 injection dose level 3 for 32 weeks、HRS9531 injection level 2 for 20 weeks

DRUG

HRS9531 injection Placebo

Placebo arm matching active arm HRS9531 injection dose level 4 for 32 weeks、HRS9531 injection level 2 for 20 weeks

Trial Locations (26)

20032

Zhongshan Hospital Affiliated to Fudan University, Shanghai

100191

Peking University Third Hospital, Beijing

110004

Shengjing Hospital Of China Medical University, Shenyang

130022

The Second Hospital of Jilin University, Changchun

150001

The Fourth Affiliated Hospital of Harbin Medical University, Harbin

200030

Zhongshan Hospital, Fudan University, Shanghai

221004

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

222001

Lianyungang Hospital of TCM, Lianyungang

222002

The First People's Hospital Of Lianyungang, Lianyungang

225001

North Jiangsu People's Hospital, Yangzhou

230601

The second affiliated hospital of Anhui medical university, Hefei

310006

The First People's Hospital of Hangzhou, Hangzhou

400010

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

430000

The Third People's Hospital of Hubei Province, Wuhan

435000

The Central Hospital Of Huangshi, Huangshi

471000

The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang

473000

The First Affiliated Hospital of Nanyang Medical College, Nanyang

510800

Huadu District People's Hospital of Guangzhou, Guangzhou

518110

The people's hospital of Longhua.Shenzhen, Shenzhen

530007

Department of Endocrinology,Sencond Affiliated Hospital of Guangxi Medical University, Nanning

570102

The First Affiliated Hospital of Hainan Medical University, Haikou

610000

Chengdu Second People's Hospital, Chengdu

650032

First Affiliated Hospital of Kunming Medical University, Kunming

710000

The First Affiliated Hospital of Xi'an Medical College, Xi'an

014040

Baotou Central Hospital, Baotou

030000

Second hospttoal of Shanxi medical University, Taiyuan

All Listed Sponsors
lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY

NCT05881837 - Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes | Biotech Hunter | Biotech Hunter